Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to:
- Evaluate the safety and pharmacokinetic profile of repeated doses IV CR845 over one week
in patients who are undergoing hemodialysis. (Part A)
- This study is also investigating whether repeated doses of IV CR845 over two weeks is
safe and effective in reducing the intensity of itching in hemodialysis patients with
uremic pruritus (Part B).